Royal Biologics Launches Umbilical Cord Graft

Royal Biologics, an ortho-biologics company specializing in the research and advancement of ortho-biologics solutions, is launching Cryo-Cord, the first DMSO-free viable umbilical cord graft. The company will be showcasing Cryo-Cord along with its new portfolio of Autologous Live Cellular (ALC) technologies at the NY20 Foundation for Podiatric Medicine meeting, held Jan. 24-26 in New York, N.Y., for more than 1500 clinical attendees.   
 
The company will feature its full suite of surgical biologic offerings. At its booth, Royal Biologics will showcase its ALC portfolio designed to personalize live regenerative healing for a wide variety of wound types across the orthopedics continuum.
 
The launch of Cryo-Cord enables providers with the first DMSO-free viable umbilical cord tissue. Cryo-Cord has been obtained with consent from healthy mothers during cesarean section delivery and is intended for use as a soft tissue barrier or wound dressing.  Cryo-Cord is processed using aseptic techniques and frozen with a proprietary cryoprotectant. 
 
“Cryo-Cord offers a new enhancement to traditional wound care therapies and we are excited to pave the way with the first DMSO-free cryoprotectant graft on the market,” said Salvatore Leo, CEO of Royal Biologics. 
 
Other featured products at NY20 will include Maxx-Cell, which was launched as the world’s most advanced bone marrow aspiration device. Maxx-Cell offers a new technique to a gold standard approach of aspirating a patient’s autologous bone marrow cells. Maxx-Cell however does not require centrifugation to deliver a final end product. The Maxx-Cell system maximizes stem and progenitor cell yields by giving the surgeon the ability to efficiently harvest bone marrow from multiple levels within the medullary space, while restricting dilution of peripheral blood. As a result, Maxx-Cell delivers a high, most pure enriched form of bone marrow aspirate without the need for centrifugation.
 
This month, the company has also announced the launch of MAGNUS, which is a DMSO-free viable cellular bone allograft and demos will be available during the conference. MAGNUS presents a unique solution to traditional viable cellular allograft technology as it utilizes a DMSO-free cryoprotectant. This novel approach to the viable cellular allograft market differentiates MAGNUS from other technologies currently available.
 
Leo added, “We are excited to participate in NY20 and share how our Autologous Live Cellular based therapies give the surgeons an efficient and effective way to enhance surgical outcomes by providing alternatives to conventional therapies for bone and soft tissue related injuries. We also believe that in a cost-conscious industry, we can provide viable cellular products that provide value at the point of care.”